Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.